Ondansetron Augmentation in Treatment-resistant OCD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Florence, Italy, 50137
- Institute of Neuroscience
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- a diagnosis of OCD established by clinical interview with a licensed psychiatrist;
- a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale
- a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose
Exclusion Criteria:
- diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, current substance dependence or abuse, and current major depressive episode preceding the onset of obsessive compulsive disorder
- undergoing concomitant behavior therapy
- or having significant cardiovascular, hepatic, renal or pulmonary diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: obsessive compulsive disorder
obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks.
Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks.
ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
|
obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks.
Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks.
ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: baseline
|
baseline
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 2
|
week 2
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 4
|
week 4
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 6
|
week 6
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 8
|
week 8
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 10
|
week 10
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 12
|
week 12
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 14
|
week 14
|
|
Yale Brown Obsessive Compulsive Scale
Time Frame: week 16
|
week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Drug Effect scale
Time Frame: week 0
|
week 0
|
|
The Drug Effect scale
Time Frame: week 2
|
week 2
|
|
The Drug Effect scale
Time Frame: week 4
|
week 4
|
|
The Drug Effect scale
Time Frame: week 6
|
week 6
|
|
The Drug Effect scale
Time Frame: week 8
|
week 8
|
|
The Drug Effect scale
Time Frame: week 10
|
week 10
|
|
The Drug Effect scale
Time Frame: week 12
|
week 12
|
|
The Drug Effect scale
Time Frame: week 14
|
week 14
|
|
The Drug Effect scale
Time Frame: week 16
|
week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stefano Pallanti, MD, University of Florence
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Anxiety Disorders
- Obsessive-Compulsive Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Anti-Anxiety Agents
- Antipruritics
- Ondansetron
Other Study ID Numbers
Other Study ID Numbers
- OND2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.